EP3341011A4 - Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen - Google Patents
Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen Download PDFInfo
- Publication number
- EP3341011A4 EP3341011A4 EP16825301.1A EP16825301A EP3341011A4 EP 3341011 A4 EP3341011 A4 EP 3341011A4 EP 16825301 A EP16825301 A EP 16825301A EP 3341011 A4 EP3341011 A4 EP 3341011A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- interleukin
- receptor
- inflammatory diseases
- peptide inhibitors
- treat inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100036672 Interleukin-23 receptor Human genes 0.000 title 1
- 101710195550 Interleukin-23 receptor Proteins 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/800,627 US9624268B2 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
PCT/US2015/040658 WO2016011208A1 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
US201562264820P | 2015-12-08 | 2015-12-08 | |
US201662281123P | 2016-01-20 | 2016-01-20 | |
PCT/US2016/042680 WO2017011820A2 (en) | 2015-07-15 | 2016-07-15 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3341011A2 EP3341011A2 (de) | 2018-07-04 |
EP3341011A4 true EP3341011A4 (de) | 2019-02-20 |
Family
ID=57757647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16825301.1A Pending EP3341011A4 (de) | 2015-07-15 | 2016-07-15 | Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP3341011A4 (de) |
JP (1) | JP6858174B2 (de) |
KR (1) | KR102513978B1 (de) |
CN (1) | CN108348580B (de) |
AU (1) | AU2016293619B2 (de) |
BR (1) | BR112018000691A2 (de) |
CA (1) | CA2991984A1 (de) |
CL (3) | CL2018000128A1 (de) |
CO (1) | CO2018000349A2 (de) |
CR (1) | CR20180029A (de) |
DO (1) | DOP2018000010A (de) |
EA (1) | EA035733B9 (de) |
EC (1) | ECSP18002929A (de) |
HK (2) | HK1257747A1 (de) |
IL (1) | IL256827A (de) |
MX (1) | MX2018000542A (de) |
NI (1) | NI201800008A (de) |
PE (1) | PE20180571A1 (de) |
PH (1) | PH12018500086A1 (de) |
SG (1) | SG10201912066SA (de) |
SV (1) | SV2018005614A (de) |
UA (1) | UA123772C2 (de) |
WO (1) | WO2017011820A2 (de) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
WO2014145561A2 (en) | 2013-03-15 | 2014-09-18 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses therof |
CN109776525B (zh) | 2013-04-19 | 2022-01-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
ES2890600T3 (es) | 2014-05-16 | 2022-01-20 | Protagonist Therapeutics Inc | Péptidos de tioéter antagonistas de integrina alfa4beta7 |
KR102482790B1 (ko) | 2014-07-17 | 2022-12-29 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | 인터루킨-23 수용체의 경구용 펩티드 억제제 및 염증성 장 질환을 치료하기 위한 그의 용도 |
WO2016054445A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
US9809623B2 (en) | 2014-10-01 | 2017-11-07 | Protagonist Therapeutics, Inc. | α4β7 peptide monomer and dimer antagonists |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
CN109195618A (zh) | 2016-03-23 | 2019-01-11 | 领导医疗有限公司 | 用于合成α4β7肽拮抗剂的方法 |
EP3570864A4 (de) * | 2017-01-18 | 2020-12-30 | Protagonist Therapeutics, Inc. | Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
EP3681900A4 (de) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | Opioidagonistpeptide und verwendungen davon |
WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
MX2020011639A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). |
BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
WO2020014646A1 (en) * | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
CN110015978B (zh) * | 2019-04-29 | 2021-03-19 | 康化(上海)新药研发有限公司 | O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法 |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CN114341161A (zh) * | 2019-07-10 | 2022-04-12 | 领导医疗有限公司 | 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途 |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
EP3819307A1 (de) * | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutische derivate von interleukin-22 |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
WO2021146454A1 (en) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
JOP20220169A1 (ar) * | 2020-01-15 | 2023-01-30 | Janssen Biotech Inc | مثبطات ببتيدية لمستقبلة انترلوكين-23 واستخدامها في معالجة الأمراض الالتهابية |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
KR20230110570A (ko) | 2020-11-20 | 2023-07-24 | 얀센 파마슈티카 엔.브이. | 인터류킨-23 수용체의 펩티드 억제제의 조성물 |
CA3215903A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
EP4352059A1 (de) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclische heterocyclen als fgfr-inhibitoren |
KR20240034223A (ko) * | 2021-07-14 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 인터류킨-23 수용체의 바이사이클릭 펩티드 억제제 |
AU2022402440A1 (en) | 2021-12-01 | 2024-05-30 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
WO2023172648A2 (en) * | 2022-03-09 | 2023-09-14 | Glympse Bio, Inc. | Fluorogenic substrates for aminopeptidase detection in biofluids |
CN114751962B (zh) * | 2022-03-17 | 2023-11-07 | 北京大学 | 订书肽、其制备方法及其制药用途 |
WO2024003313A1 (en) | 2022-06-30 | 2024-01-04 | Sanofi | New peptides as selective il-23 receptor antagonists |
US20240218014A1 (en) * | 2022-11-21 | 2024-07-04 | Janssen Pharmaceutica Nv | Synthesis of a cyclic peptide |
WO2024155547A2 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Peptide inhibitors of interleukin-23 receptor |
WO2024155551A1 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Polycyclic peptide inhibitors of interleukin-23 receptor |
WO2024163643A1 (en) | 2023-01-31 | 2024-08-08 | Janssen Pharmaceutica Nv | Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130183755A1 (en) * | 2010-03-31 | 2013-07-18 | Grant Gallagher | Therapeutic application of isolated naturally-occurring soluble truncated forms of il-23 receptor |
WO2016011208A1 (en) * | 2014-07-17 | 2016-01-21 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5942492A (en) * | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
CA2692037A1 (en) * | 2007-07-06 | 2009-01-15 | Valorisation Hsj, Societe En Commandite | Il-23 receptor antagonists and uses thereof |
CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
US9169292B2 (en) * | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
US8946150B2 (en) * | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
WO2015054500A2 (en) * | 2013-10-09 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
-
2016
- 2016-07-15 JP JP2018501178A patent/JP6858174B2/ja active Active
- 2016-07-15 EA EA201890325A patent/EA035733B9/ru not_active IP Right Cessation
- 2016-07-15 CA CA2991984A patent/CA2991984A1/en active Pending
- 2016-07-15 KR KR1020187004612A patent/KR102513978B1/ko active IP Right Grant
- 2016-07-15 CN CN201680049562.2A patent/CN108348580B/zh active Active
- 2016-07-15 BR BR112018000691A patent/BR112018000691A2/pt not_active IP Right Cessation
- 2016-07-15 SG SG10201912066SA patent/SG10201912066SA/en unknown
- 2016-07-15 PE PE2018000053A patent/PE20180571A1/es unknown
- 2016-07-15 AU AU2016293619A patent/AU2016293619B2/en active Active
- 2016-07-15 UA UAA201801482A patent/UA123772C2/uk unknown
- 2016-07-15 MX MX2018000542A patent/MX2018000542A/es unknown
- 2016-07-15 CR CR20180029A patent/CR20180029A/es unknown
- 2016-07-15 WO PCT/US2016/042680 patent/WO2017011820A2/en active Application Filing
- 2016-07-15 EP EP16825301.1A patent/EP3341011A4/de active Pending
-
2018
- 2018-01-09 PH PH12018500086A patent/PH12018500086A1/en unknown
- 2018-01-10 DO DO2018000010A patent/DOP2018000010A/es unknown
- 2018-01-10 IL IL256827A patent/IL256827A/en unknown
- 2018-01-11 NI NI201800008A patent/NI201800008A/es unknown
- 2018-01-15 SV SV2018005614A patent/SV2018005614A/es unknown
- 2018-01-15 EC ECIEPI20182929A patent/ECSP18002929A/es unknown
- 2018-01-15 CO CONC2018/0000349A patent/CO2018000349A2/es unknown
- 2018-01-15 CL CL2018000128A patent/CL2018000128A1/es unknown
- 2018-11-22 CL CL2018003322A patent/CL2018003322A1/es unknown
-
2019
- 2019-01-04 HK HK19100122.0A patent/HK1257747A1/zh unknown
- 2019-01-23 HK HK19101174.5A patent/HK1259149A1/zh unknown
-
2021
- 2021-02-09 CL CL2021000343A patent/CL2021000343A1/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130183755A1 (en) * | 2010-03-31 | 2013-07-18 | Grant Gallagher | Therapeutic application of isolated naturally-occurring soluble truncated forms of il-23 receptor |
WO2016011208A1 (en) * | 2014-07-17 | 2016-01-21 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
Non-Patent Citations (1)
Title |
---|
See also references of WO2017011820A2 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1259149A1 (zh) | 白細胞介素-23受體的肽抑制劑以及其治療炎症性疾病的用途 | |
IL285614A (en) | Oral peptide inhibitors of the interleukin-23 receptor and their use in the treatment of inflammatory bowel diseases | |
EP3570864A4 (de) | Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen | |
EP3820883A4 (de) | Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen | |
IL253796A0 (en) | Therapeutically active compounds and methods of use | |
IL251246A0 (en) | Therapeutically active compounds and methods of use | |
EP3151833A4 (de) | Mth1-inhibitoren zur behandlung von entzündungs- und autoimmunerkrankungen | |
IL250318B (en) | Protein kinase c inhibitors and methods of using them | |
EP3047024A4 (de) | Zusammensetzungen und verfahren zur behandlung von autoimmun- und entzündungserkrankungen und -leiden | |
EP3116898A4 (de) | Verwendung von aav-exprimiertem m013-protein als entzündungshemmendes therapeutikum | |
IL289628A (en) | Peptide inhibitors of the interleukin-23 receptor and their use in the treatment of inflammatory diseases | |
IL253118A0 (en) | Methods for treating inflammatory diseases | |
HK1211471A1 (en) | Treating th2-mediated diseases by inhibition of bromodomain- comprising proteins brd7 and brd9 brd7 brd9 th2 | |
HK1252037A1 (zh) | 治療炎性疾病的方法 | |
EP3157531A4 (de) | Verfahren und zusammensetzungen zur stimulierung des intestinalen enteroendokrinen systems zur behandlung von erkrankungen oder zuständen in zusammenhang damit | |
EP3503903A4 (de) | Ascarosidbehandlung von autoimmun- und entzündungserkrankungen | |
EP3148575A4 (de) | Verfahren und zusammensetzungen zur behandlung von allergie- und entzündungskrankheiten | |
EP3408413A4 (de) | Vorhersage der therapeutischen reaktion bei entzündungserkrankungen | |
EP3288379A4 (de) | Peptidzusammensetzungen und verfahren zur verwendung | |
DK3229827T3 (da) | Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme | |
EP3393460A4 (de) | Zusammensetzungen und verfahren zur behandlung von mvid und verwandten erkrankungen | |
EP3313427A4 (de) | Therapeutische peptide und verfahren zur verwendung davon | |
EP3139944A4 (de) | Verwendung eines peptids zur behandlung angiogenesebedingter erkrankungen | |
IL241934A (en) | Inhibitory peptides for the treatment of inflammatory diseases | |
EP3534932A4 (de) | Behandlung von krankheiten im zusammenhang mit igfb3 und dessen rezeptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180212 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190121 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 7/08 20060101ALI20190115BHEP Ipc: A61K 38/20 20060101AFI20190115BHEP Ipc: C07K 14/54 20060101ALI20190115BHEP Ipc: C07K 7/06 20060101ALI20190115BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1257747 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200213 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PROTAGONIST THERAPEUTICS, INC. |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230515 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0038200000 Ipc: C07K0007060000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/00 20060101ALN20240724BHEP Ipc: A61P 37/06 20060101ALI20240724BHEP Ipc: A61P 37/02 20060101ALI20240724BHEP Ipc: A61P 35/00 20060101ALI20240724BHEP Ipc: A61P 29/00 20060101ALI20240724BHEP Ipc: A61P 19/02 20060101ALI20240724BHEP Ipc: A61P 17/06 20060101ALI20240724BHEP Ipc: A61P 15/00 20060101ALI20240724BHEP Ipc: A61P 11/06 20060101ALI20240724BHEP Ipc: A61P 11/02 20060101ALI20240724BHEP Ipc: A61P 7/00 20060101ALI20240724BHEP Ipc: A61P 3/10 20060101ALI20240724BHEP Ipc: A61P 3/00 20060101ALI20240724BHEP Ipc: A61P 1/18 20060101ALI20240724BHEP Ipc: A61P 1/16 20060101ALI20240724BHEP Ipc: A61P 1/04 20060101ALI20240724BHEP Ipc: C07K 7/08 20060101ALI20240724BHEP Ipc: C07K 7/06 20060101AFI20240724BHEP |
|
INTG | Intention to grant announced |
Effective date: 20240806 |